Janus Henderson Group PLC Sells 9,257 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Janus Henderson Group PLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 210,080 shares of the biopharmaceutical company’s stock after selling 9,257 shares during the quarter. Janus Henderson Group PLC’s holdings in Alnylam Pharmaceuticals were worth $49,442,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Larson Financial Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 73 shares during the last quarter. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $33,000. OFI Invest Asset Management bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, IFP Advisors Inc lifted its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ:ALNY opened at $266.86 on Wednesday. The business’s 50-day moving average is $251.33 and its 200 day moving average is $253.69. Alnylam Pharmaceuticals, Inc. has a 1 year low of $144.73 and a 1 year high of $304.39. The firm has a market capitalization of $34.80 billion, a P/E ratio of -122.98 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the company earned ($0.16) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 20.2% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ALNY shares. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. UBS Group lifted their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Royal Bank of Canada lifted their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday, March 21st. Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $319.17.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,392 shares of company stock valued at $1,875,627 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.